✦ LIBER ✦

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

✍ Scribed by Viktor Grünwald; Pierre I. Karakiewicz; Sevil E. Bavbek; Kurt Miller; Jean-Pascal Machiels; Se-Hoon Lee; James Larkin; Petri Bono; Sun Young Rha; Daniel Castellano; Christian U. Blank; Jennifer J. Knox; Robert Hawkins; Oezlem Anak; Marianne Rosamilia; Jocelyn Booth; Nicoletta Pirotta; István Bodrogi

Book ID: 116430840
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 257 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.06.054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of vascular endothel

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

✍ Jae-Lyun Lee; Inkeun Park; Kwonoh Park; Seongjoon Park; Yongcheol Ahn; Jin-Hee A 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 317 KB

Everolimus in metastatic renal cell carc

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

✍ E. Calvo; B. Escudier; R.J. Motzer; S. Oudard; T.E. Hutson; C. Porta; S. Bracard 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Comparative efficacy of vascular endothe

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

✍ Kwonoh Park, Jae-Lyun Lee, Inkeun Park, Seongjoon Park, Yongcheol Ahn, Jin-Hee A 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 193 KB